Cancer pain can be due to the disease condition itself or may be due to the associated treatments such as surgeries, chemotherapy, and other therapies. There is surge in the demand for cancer pain drugs owing to the growth in incidence of different forms of cancer, higher number of R&D studies to develop cancer pain therapeutics, and increase in adoption of cancer pain drugs. In addition, growth in the geriatric population and wide availability of cancer pain drugs further drive the market growth. However, adverse effects associated with cancer pain are projected to impede the market growth.
Major Key Players of the Cancer Pain Market are:
Aoxing Pharmaceutical, BioDelivery Sciences International, Daiichi Sankyo Co., Grunenthal Pharma GmbH & Co. KG, Hisamitsu Pharmaceutical Co, Inc., Insys Therapeutics, Inc., Mundipharma International Limited, Orexo AB, Pfizer Inc., Teva Pharmaceutical Industries Limited
Read More @ https://www.openpr.com/news/2069644/cancer-pain-market-to-witness-growth-acceleration-during
No comments:
Post a Comment